MAAT INDEX

CLAIM #48547 · Pfizer Inc (PFE) · 2025Q1 earnings call · Apr 29, 2025 · due Dec 31, 2027

Now in total, we expect approximately $7.7 billion in savings by the end of 2027 to drive operational efficiency, strengthening our business with the potential of contributing significantly to our bottom line over this period.

David Denton · CFO

PENDING
graded after results covering Dec 31, 2027 are reported

How to check this claim

Look at: Cumulative net cost savings from cost realignment program (including SIA and R&D efficiency initiatives), as disclosed by management

It came true if: Cumulative disclosed savings >= $7.0 billion by end of 2027

Where: Company management commentary / investor presentations (earnings calls, 10-K) disclosing cumulative program savings

In context

in cumulative net cost savings from our ongoing cost realignment program by the end of this year. And today, we've announced our expectation that this program will deliver an additional $1.2 billion in net savings, primarily in SIA and in part by leveraging digital tools, including automation and AI, as well as simplification of our business processes. The savings are expected to be fully realized by the end of 2027. Furthermore, we have identified additional opportunities to drive improvements in productivity and operational efficiency in our R&D organization, again, through enhanced digital enablement as well as automation. We expect approximately $500 million in savings associated with these efforts to be realized by the end of 2026, with the savings reinvested within our R&D program. Now in total, we expect approximately $7.7 billion in savings by the end of 2027 to drive operational efficiency, strengthening our business with the potential of contributing significantly to our bottom line over this period. Now let me turn to our full-year 2025 guidance. As you are aware, the pharmaceutical industry is currently navigating a complex global landscape, shaped by rapidly evolving trade and tariff policies. Our functional team is analyzing a range of potential outcomes while developing strategies to help us mitigate the potential impact on our business in both the short as well as the long term. These actions include the management of current inventory levels in certain jurisdictions, leveraging our domestic manufacturing footprint, and the potential production of certain API and products in the US. Should we be impacted by further tariffs in the future, we will assess the impact of these policies enacted and provide information at the appropriate time. Let me now spend just a few minutes on our

Verify independently

SEC filings for PFE · Claim quote is verbatim from the 2025Q1 earnings call.